首页> 美国卫生研究院文献>Molecular Medicine >MicroRNA-218 Inhibits Cell Cycle Progression and Promotes Apoptosis in Colon Cancer by Downregulating BMI1 Polycomb Ring Finger Oncogene
【2h】

MicroRNA-218 Inhibits Cell Cycle Progression and Promotes Apoptosis in Colon Cancer by Downregulating BMI1 Polycomb Ring Finger Oncogene

机译:MicroRNA-218通过下调BMI1聚梳无名指癌基因抑制结肠癌细胞的细胞周期进程并促进其凋亡。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Deregulated miRNAs participate in colorectal carcinogenesis. In this study, miR-218 was found to be downregulated in human colorectal cancer (CRC) by miRNA profile assay. miR-218 was silenced or downregulated in all five colon cancer cells (Caco2, HT29, SW620, HCT116 and LoVo) relative to normal colon tissues. miR-218 expression was significantly lower in 46 CRC tumor tissues compared with their adjacent normal tissues (P < 0.001). Potential target genes of miR-218 were predicted and BMI1 polycomb ring finger oncogene (BMI-1), a polycomb ring finger oncogene, was identified as one of the potential targets. Upregulation of BMI-1 was detected in CRC tumors compared with adjacent normal tissues (P < 0.001) and in all five colon cancer cell lines. Transfection of miR-218 in colon cancer cell lines (HCT116, HT29) significantly reduced luciferase activity of the wild-type construct of BMI-1 3′ untranslated region (3′UTR) (P < 0.001), whereas this effect was not seen in the construct with mutant BMI-1 3′UTR, indicating a direct and specific interaction of miR-218 with BMI-1. Ectopic expression of miR-218 in HCT116 and HT29 cells suppressed BMI-1 mRNA and protein expression. In addition, miR-218 suppressed protein expression of BMI-1 downstream targets of cyclin-dependent kinase 4, a cell cycle regulator, while upregulating protein expression of p53. We further revealed that miR-218 induced apoptosis (P < 0.01), inhibited cell proliferation (P < 0.05) and promoted cell cycle arrest in the G2 phase (P < 0.01). In conclusion, miR-218 plays a pivotal role in CRC development through inhibiting cell proliferation and cycle progression and promoting apoptosis by downregulating BMI-1.
机译:失调的miRNA参与大肠癌的发生。在这项研究中,通过miRNA谱分析发现miR-218在人类大肠癌(CRC)中被下调。相对于正常结肠组织,所有五个结肠癌细胞(Caco2,HT29,SW620,HCT116和LoVo)中的miR-218均被沉默或下调。与邻近的正常组织相比,在46个CRC肿瘤组织中miR-218的表达显着降低(P <0.001)。预测了miR-218的潜在靶基因,并将BMI1多梳无名指癌基因(BMI-1)(一种多梳无名指癌基因)鉴定为潜在靶标之一。与邻近的正常组织相比,在CRC肿瘤中检测到BMI-1上调(P <0.001),并且在所有五个结肠癌细胞系中都检测到。在结肠癌细胞系(HCT116,HT29)中转染miR-218显着降低了BMI-1 3'非翻译区(3'UTR)的野生型构建体的荧光素酶活性(P <0.001)在具有突变体BMI-​​1 3'UTR的构建体中的表达,表明miR-218与BMI-1的直接和特异性相互作用。 miR-218在HCT116和HT29细胞中异位表达可抑制BMI-1 mRNA和蛋白表达。另外,miR-218抑制了细胞周期调节因子cyclin依赖性激酶4的BMI-1下游靶标的蛋白表达,同时上调了p53的蛋白表达。我们进一步揭示了miR-218诱导细胞凋亡(P <0.01),抑制细胞增殖(P <0.05)和促进细胞周期停滞在G2期(P <0.01)。总之,miR-218通过抑制细胞增殖和周期进程并通过下调BMI-1促进细胞凋亡,在CRC的发展中起关键作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号